Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers
A Comparative Study of Diosmin-Hesperidin and Loratadine for the Prevention of G-CSF Induced Bone Pain in Patients With Hematological Malignancies
Alexandria University
88 participants
Mar 1, 2025
INTERVENTIONAL
Conditions
Summary
This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain. The study is comparing two oral medications for their effectiveness as a preventive treatment: * Diosmin-Hesperidin (a flavonoid supplement). * Loratadine (a common anti-allergy medication). The core question the study is trying to answer is: * Is diosmin-hesperidin effective in preventing G-CSF-induced bone pain compared to loratadine? * Does the combination of diosmin-hesperidin and loratadine offer better pain prevention than either drug alone?
Eligibility
Inclusion Criteria5
- Adults 18 to 65 years old
- Receiving a G-CSF for one of the following indications:
- Treatment of neutropenia along with treatment for leukemia or lymphoma Neutropenia prevention following autologous hematopoietic cell transplant
- Patients with or without bone pain associated with G-CSF administration.
- Willingness to provide informed consent to participate in the study.
Exclusion Criteria7
- Patients with solid tumors.
- Pregnant or breastfeeding women.
- Patients with known allergies or hypersensitivity to Loratadine, Diosmin- Hespiridin or Filgrastim.
- Patients with pre-existing bone disorders or receiving bone modifying agents
- Chronic use of antihistamines, Diosmin-Hespiridin, NSAIDs, corticosteroids, or immunosuppressants.
- Receiving medications with drug interaction grade X with Loratadine, Diosmin-Hespiridin or Filgrastim
- Patients who are unable to understand or provide informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Loratadine 10 mg oral tablet administered once daily, starting 30 minutes before filgrastim administration and continued for 5 consecutive days.
Diosmin-Hesperidin 500 mg oral tablet administered twice daily, starting 30 minutes before daily filgrastim administration and continued for 5 consecutive days.
Combination of Loratadine 10 mg oral tablet once daily plus Diosmin-Hesperidin 500 mg oral tablet twice daily, starting 30 minutes before daily filgrastim administration and continued for 5 consecutive days.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07300735